Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.35 |
| ▸ | PHGDH | O43175 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966086 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL966083 | 0.84 | MAPT (0.36) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL966082 | 0.84 | MAPT (0.36) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL963534 | 0.82 | MAPT (0.35) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL962582 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL962581 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL962500 | 0.81 | L3MBTL1 (0.50) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL962501 | 0.81 | L3MBTL1 (0.50) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL963702 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTNR2F2HTTMAPK8 | |
| SCHEMBL966085 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTNR2F2HTTMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | SMN1; SMN2 4710/4885MAPT 4720/4885NR2F2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.